Aktis Oncology (AKTS) director Todd Foley reports holdings in Form 3 filing

Q: What does the Todd Foley Form 3 filing for AKTS disclose?

The Form 3 shows that Todd Foley , a director and 10% owner of Aktis Oncology, Inc. (AKTS) , has indirect interests in several series of preferred stock and a direct stock option for 37,866 shares of common stock at an exercise price of $18 per share.

Q: How many preferred shares linked to Todd Foley are reported in the AKTS Form 3?

Entities associated with Todd Foley hold 597,391 Series Seed , 2,688,270 Series A , and 716,872 Series B Redeemable Convertible Preferred shares of Aktis Oncology , as disclosed in the filing.

Q: How are the Aktis Oncology preferred shares convertible according to the Form 3?

Each share of Series Seed, Series A, and Series B Redeemable Convertible Preferred Stock is convertible into common stock of Aktis Oncology on a 3.8044‑for‑1 basis, with conversion occurring upon the closing of the company’s initial public offering.

Q: What does the Form 3 say about Todd Foley’s beneficial ownership of AKTS preferred shares?

The filing states that Todd Foley disclaims beneficial ownership of the preferred securities except to the extent of his pecuniary interest , while the shares are held by investment entities such as MPM BioVentures 2018, L.P. and related funds.

Q: What are the key terms of Todd Foley’s stock option in Aktis Oncology?

The Form 3 reports a stock option for 37,866 shares of Aktis Oncology common stock with an exercise price of $18 per share. One‑thirty‑sixth of the option vests in monthly installments from January 8, 2026 , subject to his continuous service through each vesting date.

Q: Who actually holds the preferred shares reported in the AKTS Form 3 for Todd Foley?

The preferred shares are held by entities including MPM BioVentures 2018, L.P. , MPM BioVentures 2018 (B), L.P. , and MPM Asset Management Investors BV2018 LLC . The filing notes that Foley is a managing director of MPM BioVentures 2018 LLC and that these entities are the direct or indirect holders.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Aktis Oncology director and 10% owner Todd Foley filed a Form 3 detailing his indirect and direct interests in the company’s securities as of January 8, 2026. Investment entities associated with him hold 597,391 shares of Series Seed Redeemable Convertible Preferred Stock, 2,688,270 shares of Series A Redeemable Convertible Preferred Stock, and 716,872 shares of Series B Redeemable Convertible Preferred Stock, each series convertible into common stock on a 3.8044‑for‑1 basis upon the closing of the company’s initial public offering. Foley disclaims beneficial ownership of these preferred shares except to the extent of his pecuniary interest. He also directly holds a stock option for 37,866 shares of common stock at an exercise price of $18 per share, vesting in equal monthly installments over 36 months starting January 8, 2026, conditioned on continued service.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Foley Todd

Role Director, 10% Owner

Type	Security	Shares	Price	Value
holding	Series Seed Redeemable Convertible Preferred Stock	--	--	--
holding	Series A Redeemable Convertible Preferred Stock	--	--	--
holding	Series B Redeemable Convertible Preferred Stock	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Series Seed Redeemable Convertible Preferred Stock — 597,391 shares (Indirect, See Footnote); Series A Redeemable Convertible Preferred Stock — 2,688,270 shares (Indirect, See Footnote); Series B Redeemable Convertible Preferred Stock — 716,872 shares (Indirect, See Footnote); Stock Option (Right to Buy) — 37,866 shares (Direct)

Footnotes (6)

F1. Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock have no expiration date.
F2. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F3. The shares are held as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC.
F4. The shares are held as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018.
F5. The shares are held as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018.
F6. 1/36th of the original number of shares subject to the option shall vest in monthly installments from January 8, 2026, subject to the Reporting Person's continuous service through each vesting date, inclusive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 01/08/2026 - 09:03 PM

FAQ

What does the Todd Foley Form 3 filing for AKTS disclose?

The Form 3 shows that Todd Foley, a director and 10% owner of Aktis Oncology, Inc. (AKTS), has indirect interests in several series of preferred stock and a direct stock option for 37,866 shares of common stock at an exercise price of $18 per share.

How many preferred shares linked to Todd Foley are reported in the AKTS Form 3?

Entities associated with Todd Foley hold 597,391 Series Seed, 2,688,270 Series A, and 716,872 Series B Redeemable Convertible Preferred shares of Aktis Oncology, as disclosed in the filing.

How are the Aktis Oncology preferred shares convertible according to the Form 3?

Each share of Series Seed, Series A, and Series B Redeemable Convertible Preferred Stock is convertible into common stock of Aktis Oncology on a 3.8044‑for‑1 basis, with conversion occurring upon the closing of the company’s initial public offering.

What does the Form 3 say about Todd Foley’s beneficial ownership of AKTS preferred shares?

The filing states that Todd Foley disclaims beneficial ownership of the preferred securities except to the extent of his pecuniary interest, while the shares are held by investment entities such as MPM BioVentures 2018, L.P. and related funds.

What are the key terms of Todd Foley’s stock option in Aktis Oncology?

The Form 3 reports a stock option for 37,866 shares of Aktis Oncology common stock with an exercise price of $18 per share. One‑thirty‑sixth of the option vests in monthly installments from January 8, 2026, subject to his continuous service through each vesting date.

Who actually holds the preferred shares reported in the AKTS Form 3 for Todd Foley?

The preferred shares are held by entities including MPM BioVentures 2018, L.P., MPM BioVentures 2018 (B), L.P., and MPM Asset Management Investors BV2018 LLC. The filing notes that Foley is a managing director of MPM BioVentures 2018 LLC and that these entities are the direct or indirect holders.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Foley Todd

(Last)

(First)

(Middle)

C/O MPM BIOIMPACT LLC

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON

02116

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series Seed Redeemable Convertible Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	597,391	$0⁽¹⁾	I	See Footnote⁽²⁾⁽³⁾
Series A Redeemable Convertible Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	2,688,270	$0⁽¹⁾	I	See Footnote⁽²⁾⁽⁴⁾
Series B Redeemable Convertible Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	716,872	$0⁽¹⁾	I	See Footnote⁽²⁾⁽⁵⁾
Stock Option (Right to Buy)	⁽⁶⁾	01/07/2036	Common Stock	37,866	$18	D

Explanation of Responses:

1. Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock have no expiration date.

2. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

3. The shares are held as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC.

4. The shares are held as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018.

5. The shares are held as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018.

6. 1/36th of the original number of shares subject to the option shall vest in monthly installments from January 8, 2026, subject to the Reporting Person's continuous service through each vesting date, inclusive.

	/s/ Todd Foley	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR